RxDoctor Payments Data

Abdul Rezahi, MD

General Practice · Longwood, FLNPI 1972119113

Payments from drug & device makers

$562in general payments, 2019–2025

Across 23 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$200
  • Novo Nordisk$174
  • Amgen$68
  • Biohaven Pharmaceutical Holding Company Ltd.$32
  • Scpharmaceuticals Inc.$26
  • Pfizer$25
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$25,795
Medicare patients
129
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$65,023
OzempicSemaglutide46$61,267
EliquisApixaban50$43,618
FarxigaDapagliflozin Propanediol27$30,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,372
XareltoRivaroxaban11$12,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,863
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,062
Albuterol Sulfate HfaAlbuterol Sulfate60$2,265
Atorvastatin Calcium226$2,018
Levothyroxine Sodium103$2,017
Gabapentin134$1,877
Rosuvastatin Calcium133$1,623
Omeprazole90$1,245
Isosorbide Dinitrate12$1,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$65,02346 claims
Novo NordiskOzempic$174$61,26746 claims
PfizerEliquis$25$43,61850 claims
AstraZenecaFarxiga$21$30,21127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →